EWTX

Edgewise Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth 2/10
  • Momentum 8/10
Edgewise Therapeutics sales and earnings growth
EWTX Growth
Fair
  • Revenue Y/Y 0.00%
  • EPS Y/Y -5.33%
  • FCF Y/Y -20.47%
Edgewise Therapeutics gross and profit margin trends
EWTX Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC -33.30%
Edgewise Therapeutics net debt vs free cash flow
EWTX Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Edgewise Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗